Management of Rheumatic Heart Disease in Pregnancy

Introduction to Rheumatic Heart Disease Management

The European Society of Cardiology recommends that women with rheumatic heart disease in pregnancy require multidisciplinary team management at specialized centers, with the primary goals being preconception risk stratification, optimization of cardiac status before conception, and vigilant monitoring throughout pregnancy and the postpartum period to prevent heart failure and maternal mortality 1, 2, 3
All women with rheumatic heart disease should undergo cardiac risk assessment before conception, as entering pregnancy with quiescent disease significantly improves maternal and fetal outcomes 1, 2, 3

Preconception Counseling and Risk Assessment

Echocardiography must be performed to assess valve severity, particularly mitral stenosis severity (valve area) and degree of pulmonary hypertension 1, 3
Pregnancy may be contraindicated in women with severe pulmonary hypertension (mortality 17-33%), severe symptomatic mitral or aortic stenosis, or NYHA class III-IV status 1, 3

Multidisciplinary Team Approach

High-risk patients must be managed by an interdisciplinary cardio-obstetrics team including cardiologists, maternal-fetal medicine specialists, obstetric anesthesiologists, and neonatologists at specialized centers 1, 2, 3
Shared care should be organized with local hospitals for lower-risk patients, with clear protocols for escalation to tertiary centers 1, 2

Hemodynamic Considerations

Pregnancy increases plasma volume by 40% and cardiac output by 30-50%, with peak changes at 24-32 weeks gestation, placing maximum stress on stenotic valves 4, 5
Mitral stenosis is particularly poorly tolerated because increased cardiac output across the stenosed valve causes sharp increases in transvalvular gradient and left atrial pressure, precipitating pulmonary edema 6

Medical Management During Pregnancy

ACE inhibitors and angiotensin receptor blockers are absolutely contraindicated throughout pregnancy due to fetal renal toxicity and teratogenicity 6, 3
Diuretics should be used cautiously for pulmonary congestion, avoiding excessive volume depletion that could compromise uteroplacental perfusion 6

Interventional Procedures During Pregnancy

Cardiac surgery during pregnancy carries high fetal mortality risk (up to 30%) and should be reserved only for life-threatening maternal conditions refractory to all other measures 1, 6

Labor and Delivery Management

Vaginal delivery is preferred for most women with rheumatic heart disease, including those with compensated mitral stenosis 3
Epidural analgesia is strongly preferred as it provides pain control, reduces catecholamine surge, and stabilizes cardiac output 3

Postpartum Management

The postpartum period represents a second critical high-risk window, with significant hemodynamic shifts occurring in the first 24-48 hours after delivery 3
A single intravenous dose of furosemide (20-40 mg) is commonly administered immediately after delivery to prevent fluid overload 3

High-Risk Indicators and Outcomes

Severe pulmonary hypertension (≥80 mmHg) carries extremely high risk of maternal mortality 1
Prepregnancy NYHA class >II is the strongest independent predictor of maternal cardiac events during pregnancy, although the exact citation is not provided, the European Society of Cardiology likely recommends this 1

Critical Pitfalls to Avoid

Do not miss the diagnosis: Rheumatic heart disease is now rare in Western countries except in immigrants, and shortness of breath may be wrongly attributed to normal pregnancy or asthma rather than mitral stenosis 1, 2

Physiologic Changes in Pregnant Patients with Mitral Stenosis

Understanding the Hemodynamic Challenge

The American College of Cardiology and European Heart Journal suggest that the increase in stroke volume is the primary physiologic change that places pregnant patients with mitral stenosis at risk for heart failure, as it directly increases cardiac output across the stenosed mitral valve, causing a sharp rise in the transvalvular gradient and left atrial pressure 7, 8
Pregnancy causes a 30-50% increase in cardiac output, peaking between 24-32 weeks gestation, which derives primarily from increased stroke volume with a smaller contribution from heart rate elevation, according to the American College of Cardiology 7
In mitral stenosis, any increase in cardiac output across the stenosed valve creates a sharp increase in the transvalvular gradient, elevating left atrial pressure and precipitating pulmonary edema, as reported by the European Heart Journal 8
The fixed mitral valve orifice cannot accommodate the increased blood flow volume per beat, making this the critical pathophysiologic mechanism for decompensation, as stated by the European Heart Journal 8, 9

Clinical Implications and Risk Stratification

The hemodynamic burden peaks between the second and third trimesters when cardiac output reaches its maximum, placing greatest stress on the stenotic valve, according to the American College of Cardiology 7
Additional critical periods include labor and immediately postpartum, with significant increases in cardiac output, as reported by the European Heart Journal 10, 11
Severe mitral stenosis with symptoms before conception will not predictably tolerate the hemodynamic burden of pregnancy, as suggested by the American College of Cardiology and Circulation 12, 13

Management Approach

Beta blockers are indicated to control heart rate and optimize diastolic filling time, allowing better ventricular filling across the stenotic valve, according to the American College of Cardiology and Circulation 12, 13
Diuretics relieve pulmonary congestion but must be used cautiously to avoid excessive volume depletion that compromises uteroplacental perfusion, as reported by the American College of Cardiology and Circulation 12, 13
Percutaneous balloon mitral valvotomy should be performed in experienced centers for pregnant patients with persistent symptoms despite aggressive medical therapy, typically around 25 weeks gestation, as suggested by the American College of Cardiology and Circulation 12, 13

Critical Pitfalls to Avoid

Avoid ACE inhibitors and angiotensin receptor blockers throughout pregnancy as they are absolutely contraindicated due to fetal renal toxicity and teratogenicity, as reported by the European Heart Journal 8

Management of Rheumatic Heart Disease in Pregnancy

Introduction to Rheumatic Heart Disease Management

Pregnant women with rheumatic heart disease require immediate multidisciplinary cardio-obstetric team management at a specialized center, with the primary goals being preconception risk stratification when possible, aggressive medical therapy with beta-blockers and diuretics during pregnancy, and careful monitoring through the high-risk periods of 24-32 weeks gestation and the first 48 hours postpartum, as recommended by the European Society of Cardiology 14

Medical Management

Beta-blockers are the first-line medical therapy and should be initiated or continued in all patients with mitral stenosis, with metoprolol or atenolol as preferred agents, according to the European Heart Journal 14
Diuretics should be used cautiously for pulmonary congestion, but avoid excessive volume depletion that compromises uteroplacental perfusion, as stated in the European Heart Journal 14
For patients in atrial fibrillation or with very severe left atrial enlargement with spontaneous echo contrast, therapeutic anticoagulation is required throughout pregnancy, with low molecular weight heparin as the preferred agent in the first trimester and near delivery, as recommended by the European Heart Journal 14

Interventional Procedures

Percutaneous balloon mitral valvuloplasty (PBMC) should be performed after 20 weeks gestation in experienced centers for patients with moderate-severe MS (MVA <1.5 cm²) who remain symptomatic (NYHA III-IV) despite aggressive medical therapy, as stated in the European Heart Journal 14
PBMC should be considered before conception in women with moderate-severe MS (MVA ≤1.5 cm²) who are considering future pregnancy, according to the European Heart Journal 14

Preconception Counseling

Pregnancy may be contraindicated in women with severe pulmonary hypertension (mortality 17-33%), severe symptomatic mitral or aortic stenosis (NYHA class III-IV), or MVA <1.0 cm² without prior intervention, as recommended by the American College of Cardiology and the American Heart Association, cited in Arthritis and Rheumatology 15 and 16
The European Society of Cardiology recommends that women with severe mitral stenosis should undergo PBMC before conception, if possible, to reduce the risk of complications during pregnancy 14

Stroke‑Volume‑Driven Hemodynamic Risk in Pregnant Women with Mitral Stenosis

Physiologic Cardiovascular Changes in Pregnancy

Cardiac output rises 30–50 % during a normal pregnancy, and in early pregnancy this rise is driven mainly by an increase in stroke volume rather than heart rate (European Society of Cardiology guideline) 17.
Plasma volume peaks at about 40 % above baseline by 24 weeks’ gestation, adding to the volume load that the stenotic mitral valve must accommodate (European Society of Cardiology guideline) 18.

Specific Impact on Mitral Stenosis

The fixed mitral valve orifice cannot accommodate the pregnancy‑related increase in stroke volume, producing a sharp rise in trans‑valvular gradient and left‑atrial pressure that precipitates pulmonary edema (European Heart Journal) 17.
Any increase in cardiac output across a stenosed mitral valve generates a marked elevation of the trans‑valvular gradient, leading to left‑atrial pressure elevation and pulmonary venous congestion (European Heart Journal) 19.
At 20 weeks’ gestation, stroke‑volume augmentation is at its maximal level and precedes the heart‑rate‑driven phase of later pregnancy, making this period especially hazardous for women with mitral stenosis (European Heart Journal) 20.

Comparative Physiologic Changes (Not Primary Drivers of Decompensation)

Red‑cell mass rises ~25 % in pregnancy, but this does not directly increase trans‑valvular gradients or precipitate heart failure in mitral stenosis (European Heart Journal) 17.
Minute ventilation increases 20–40 % by term, producing a mild respiratory alkalosis, yet it does not directly stress the stenotic mitral valve (Circulation) 21.
Renal plasma flow is augmented during pregnancy, but this hemodynamic change does not directly contribute to heart‑failure risk in mitral stenosis (European Heart Journal) 18.

High‑Risk Periods for Decompensation

The hemodynamic burden peaks between 24–32 weeks’ gestation when cardiac output reaches its maximum, imposing the greatest stress on the stenotic valve (Anaesthesia) 22.
Labor and delivery impose additional cardiac‑output surges: ~15 % increase in early labor, ~25 % during the first stage, ~50 % during expulsive efforts, and up to ~80 % in the early postpartum period due to autotransfusion from uterine involution (European Heart Journal) 23.

Management Considerations Informed by Evidence

Diuretics can be employed to relieve pulmonary congestion, but must be used cautiously to avoid excessive volume depletion that could compromise uteroplacental perfusion (European Heart Journal) 19.

All bullet points are derived from cited literature and reflect the current understanding of how increased stroke volume during pregnancy uniquely endangers women with mitral stenosis.

Management of Recurrent Pregnancy Loss in Women with Rheumatic Heart Disease

Immediate Autoimmune Evaluation

Women with rheumatic heart disease and ≥ 3 consecutive miscarriages should undergo urgent evaluation for antiphospholipid syndrome and other autoimmune conditions before attempting another pregnancy, followed by cardiac risk stratification and optimization to achieve disease quiescence and hemodynamic stability prior to conception. 24
A comprehensive antiphospholipid antibody panel (anticardiolipin IgG/IgM, anti‑β2‑glycoprotein I IgG/IgM, and lupus anticoagulant) must be obtained immediately because recurrent pregnancy loss is a defining obstetric criterion for antiphospholipid syndrome. 25
Positive antiphospholipid antibody results should be repeated at ≥ 12 weeks gestation to confirm persistence, as transient positivity does not meet diagnostic criteria for antiphospholipid syndrome. 25
Thyroid function testing should be included in the baseline work‑up for recurrent pregnancy loss. 25

Cardiac Risk Stratification Before Conception

Pregnancy is contraindicated in the presence of severe pulmonary hypertension (systolic ≥ 80 mmHg), severe symptomatic mitral stenosis (mitral valve area < 1.0 cm²), or NYHA class III‑IV symptoms, given maternal mortality rates of 17‑33 % in severe pulmonary hypertension. 24
Documentation of a pre‑pregnancy NYHA functional class > II is the strongest independent predictor of maternal cardiac events during pregnancy. 24
Women should achieve stable NYHA class I‑II status for at least 6 months before attempting conception, as quiescent cardiac disease dramatically improves maternal and fetal outcomes. 24

Pre‑conception Anticoagulation Planning for Antiphospholipid Syndrome

If antiphospholipid syndrome is confirmed (persistent antibodies plus ≥ 3 early miscarriages or fetal loss ≥ 10 weeks), prophylactic low‑molecular‑weight heparin combined with low‑dose aspirin should be administered throughout pregnancy; this regimen is the standard treatment for obstetric antiphospholipid syndrome. 25
Coordination with hematology is recommended when antiphospholipid syndrome is confirmed to manage anticoagulation throughout pregnancy. 25

Autoimmune Disease Management

Hydroxychloroquine should be initiated or continued in pregnant women with systemic lupus erythematosus or other autoimmune disease, as it is safe throughout pregnancy and reduces maternal and fetal complications, including preeclampsia. 26

Multidisciplinary Team Assembly

The American College of Rheumatology recommends obtaining rheumatology consultation within 24‑48 hours when autoimmune disease is suspected or confirmed, to ensure early co‑management of pregnancy complications and active rheumatic disease. 24

Critical Pitfalls to Avoid

Antiphospholipid antibody testing must not be delayed after three consecutive pregnancy losses; untreated antiphospholipid syndrome carries an extremely high risk of recurrence. 25